Semperit (SEM) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
17 Dec, 2025Executive summary
Q3 2025 EBITDA rose to €21.3 million, up 92% from Q1 and 9% from Q2, with a 28.7% year-over-year increase; earnings after tax turned positive at €2.8 million, reversing prior losses.
Order intake and backlog now exceed 2024 levels, supporting confidence for year-end; positive momentum after a weak Q1.
Additional cost savings initiatives will reduce annual costs by €10 million.
Faced challenging markets in early 2025 due to US tariff policy and weak customer investment, but improved earnings from Q2 onward through cost reductions.
Financial highlights
Revenue for the first nine months of 2025 was €483.4 million, down 4.6% year-over-year; EBITDA at €52.0 million, down 18.6%; EBIT at €11.8 million, down 55.9%.
Q3 2025 revenue was €162.9 million (+1.1% YoY); EBITDA margin for Q1-3 2025 at 10.8% (Q1-3'24: 12.6%).
Free cash flow stable at €22.3 million; net financial debt/EBITDA at 1.5x; equity ratio at 47%.
Dividend of €0.50 per share (€10.3 million) paid in April 2025.
Operating EBITDA for the first three quarters was €55.6 million, including €3.5 million in One ERP project costs.
Earnings after tax for the first nine months were negative €8.4 million, impacted by a €3.3 million impairment and €4.2 million negative currency effects.
Outlook and guidance
Full-year 2025 operating EBITDA expected at approximately €78 million, before €5 million in One ERP project costs.
CapEx for 2025 projected at €40 million, with €30 million for maintenance and €10 million for strategic growth.
Seasonality expected in 2026, with a slower start and stronger second half.
Midterm growth drivers include German infrastructure, EU defense budgets, and Ukraine reconstruction.
Latest events from Semperit
- Operating EBITDA beat guidance and margin rebounded; 2026 targets growth and higher profitability.SEM
Q4 202518 Mar 2026 - EBITDA up 7.9% to €47.3m, medical business divested, and cost savings exceeded targets.SEM
Q2 20241 Feb 2026 - EBITDA up 11.9% to EUR 63.9m, profit positive, and 2024 guidance reaffirmed.SEM
Q3 202416 Jan 2026 - EBITDA up 21%, earnings positive, and free cash flow nearly doubled despite weak demand.SEM
Q4 202424 Dec 2025 - Q1 2025 saw steep profit declines, improved cash flow, and cautious optimism for H2 recovery.SEM
Q1 202526 Nov 2025 - Q2 recovery lifted order intake and margins; full-year EBITDA guidance and CapEx confirmed.SEM
Q2 202523 Nov 2025